The Limitations of EQ-5D as a Clinical Outcome Assessment Tool-Reference-Cited by-同舟云学术

The Limitations of EQ-5D as a Clinical Outcome Assessment Tool

Published:2024-03-11 Issue:3 Volume:17 Page:215-217
ISSN:1178-1653
Container-title:The Patient - Patient-Centered Outcomes Research
language:en
Short-container-title:Patient

Author:

Gnanasakthy Ari^ORCID,DeMuro Carla Romano

Funder

None

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40271-024-00683-w.pdf

Reference10 articles.

1. Shaw C, Longworth L, Bennett B, McEntee-Richardson L, Shaw JW. A review of the use of EQ-5D for clinical outcome assessment in health technology assessment, regulatory claims, and published literature. The Patient Patient Centered Outcomes Res. 2023. https://doi.org/10.1007/s40271-023-00662-7.

2. Devlin NJ, Brooks R. EQ-5D and the EuroQol Group: past, present and future. Appl Health Econ Health Policy. 2017;15(2):127–37. https://doi.org/10.1007/s40258-017-0310-5.

3. NICE. Guide to the Methods of Technology Appraisal. 2004. https://assets.publishing.service.gov.uk/media/5a7a5acee5274a34770e6144/NICE_guide_to_the_methods_of_technology_appraisal.pdf. Accessed 10 Feb 2024.

4. Kennedy-Martin M, Slaap B, Herdman M, van Reenen M, Kennedy-Martin T, Greiner W, et al. Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. Eur J Health Econ. 2020;21(8):1245–57. https://doi.org/10.1007/s10198-020-01195-8.

5. Gnanasakthy A, Levy C, Norcross L, Doward L, Winnette R. A review of labeling based on patient-reported outcome endpoints for New Oncology Drugs Approved by the European Medicines Agency (2017–2021). Value Health. 2023;26(6):893–901. https://doi.org/10.1016/j.jval.2023.01.017.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estimating an EQ-5D-Y-3L Value Set for Brazil;PharmacoEconomics;2024-07-02